Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.66 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325743 | 0.80 | CRBN (0.66) | CRBNDDB1MGLLHCAR1HPGD | |
| SCHEMBL23120610 | 0.80 | CRBN (0.66) | CRBNDDB1FAAHMGLLHCAR1 | |
| SCHEMBL1380327 | 0.80 | CRBN (0.66) | CRBNDDB1HCAR1HTTALDH1A1 | |
| SCHEMBL25207533 | 0.80 | CRBN (0.66) | CRBNDDB1MGLLPOLBNPSR1 | |
| SCHEMBL1530734 | 0.79 | CRBN (1.00) | CRBNDDB1HCAR1GSK3AGSK3B | |
| SCHEMBL7468085 | 0.77 | CRBN (0.61) | CRBNDDB1HCAR1HTTGSK3A | |
| SCHEMBL793922 | 0.76 | FAAH (0.41) | CRBNDDB1FAAHMGLLHSD17B10 | |
| SCHEMBL3911586 | 0.76 | CRBN (0.66) | CRBNDDB1HCAR1ALDH1A1PKM | |
| SCHEMBL5289086 | 0.76 | CRBN (0.59) | CRBNDDB1HCAR1HSD17B10HPGD | |
| SCHEMBL23345977 | 0.76 | CRBN (0.59) | CRBNDDB1HCAR1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354195-A1 | METHOD OF SCREENING | UNIV DUNDEE (GB) | 2025-11-20 | — | — | US | disclosed |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4434980-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023088477-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | 杭州和正医药有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3887358-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166076-A | Heterocyclic compounds for the treatment of epilepsy | 大塚制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020111263-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | CRBN 3575/4885DDB1 4483/4885FAAH 448/4885 |
| US-20250354195-A1 | METHOD OF SCREENING | PAICS, COASY, ABCG2 | CRBN 1827/4885DDB1 797/4885FAAH 2141/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | CRBN 3747/4885DDB1 4632/4885FAAH 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.